Ac t i o n | Pharmaron reported 1H26 revenue of Rmb7.6bn (+18% yoy) and net profit of Rmb750mn (+7% yoy or +9% excl. one-offs; or +20% yoy on a non-IFRS adjusted basis), in line with profit alert. GM slightly contracted to 32.6% from 33.7% in 1H25, reflecting USD depreciation headwind. For the same reason, OPM also lowered to 13.4% in 1H26 from 14.4%. Importantly, mgmt. raised 2026 revenue growth guidance to 15%–20% yoy from 12-18% yoy, led by both strong lab service and CDMO demand. New orders grew 30%+ yo ...

August 21, 2026 01:45 PM GMT Pharmaron | Asia Pacific M Update Call and NDR Takeaways Key Takeaways CDMO pipeline: By midyear, Pharmaron had 45 PPQs and commercial validations, spanning APIs, intermediates, and formulations. Most programs are at the PPQ stage, with further late-stage conversions expected from 2H26 on. Management highlighted that several pipeline programs address large indications and unmet medical needs, prompting clients to seek scalable and stable capacity ahead of commercialization. With ...